Clinical trial
A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT07819396 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- June 1, 2031
- Enrollment
- 52 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute biphenotypic leukemia, acute leukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, blastic plasmacytoid dendritic cell neoplasm, burkitt leukemia, burkitt lymphoma, chronic myeloid leukemia, bcr-abl1 positive, lymphoblastic lymphoma, mast cell leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome